GlobeNewswire
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
📈
AI Sentiment
Highly Positive
10/10
- Home
- NSPR
NSPR
InspireMD Inc.
as of 01-13-2026 11:37am EST
$1.57
$0.05
-3.09%
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 81.8M | IPO Year: | N/A |
| Target Price: | $4.00 | AVG Volume (30 days): | 48.1K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.58 - $3.80 | Next Earning Date: | 11-04-2025 |
| Revenue: | $7,779,000 | Revenue Growth: | 14.04% |
| Revenue Growth (this year): | 22.76% | Revenue Growth (next year): | 75.45% |
AI-Powered NSPR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 64.05%
64.05%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of InspireMD Inc. (NSPR)
Stuka Paul
Buy
Director
NSPR Dec 9, 2025
Avg Cost/Share
$1.81
Shares
5,073
Total Value
$9,182.13
Owned After
391,628
SEC Form 4
Stuka Paul
Buy
Director
NSPR Dec 5, 2025
Avg Cost/Share
$1.86
Shares
5,073
Total Value
$9,435.78
Owned After
391,628
SEC Form 4
Stuka Paul
Buy
Director
NSPR Dec 4, 2025
Avg Cost/Share
$1.85
Shares
10,130
Total Value
$18,740.50
Owned After
391,628
SEC Form 4
Stuka Paul
Buy
Director
NSPR Nov 12, 2025
Avg Cost/Share
$1.62
Shares
13,431
Total Value
$21,758.22
Owned After
391,628
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Stuka Paul | NSPR | Director | Dec 9, 2025 | Buy | $1.81 | 5,073 | $9,182.13 | 391,628 | |
| Stuka Paul | NSPR | Director | Dec 5, 2025 | Buy | $1.86 | 5,073 | $9,435.78 | 391,628 | |
| Stuka Paul | NSPR | Director | Dec 4, 2025 | Buy | $1.85 | 10,130 | $18,740.50 | 391,628 | |
| Stuka Paul | NSPR | Director | Nov 12, 2025 | Buy | $1.62 | 13,431 | $21,758.22 | 391,628 |
Latest InspireMD Inc. News
NSPR Breaking Stock News: Dive into NSPR Ticker-Specific Updates for Smart Investing
Simply Wall St.
InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago
📉
AI Sentiment
Negative
3/10
Compare NSPR vs Leading Stocks
See how NSPR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NSPR InspireMD Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.